Venus MedTech (HangZhou) Inc.
Room 201, Shuiyou Building,
No.3738, Nanhuan Road, Binjiang District
Hangzhou
Zhejiang
China
Tel: 0571-87772183
Fax: 0571-87772179
Website: http://en.venusmedtech.com/
Email: venus@venusmedtech.com
About Venus MedTech (HangZhou) Inc.
Venus MedTech (HangZhou) Inc. is located in Hangzhou National High-tech Industrial Development Zone (Binjiang), with its products positioned in the development and industrialization of international advanced interventional artificial cardiac valve system, filling up the blank in China.Interventional artificial aortic valve products researched and developed by the company takes the lead in finishing clinical tests in China. In reference to the development and promotion conditions of coronary stents at home and abroad, interventional artificial cardiac valve, as a revolutionary treatment means, has been increasingly recognized by experts, and will take on an explosible increase of clinical needs in the foreseeable next few years.
YEAR FOUNDED:
2009
PRODUCTS:
All Products
22 articles about Venus MedTech (HangZhou) Inc.
-
VenusP-Valve granted IDE approval for clinical trial, unveiling a new chapter for Chinese valve solutions globally
8/7/2023
Recently, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced the Investigational Device Exemption full approval for its in-house developed VenusP-Valve from the U.S. Food and Drug Administration.
-
Venus Medtech to showcase its structural heart treatments at London Valves 2022
11/25/2022
Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The company will present its products at the conference taking place at the ExCeL London November 27-29, 2022 in its booth (#25), during a symposium, and at the official launch of the TARGET multicenter clinical study.
-
Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence
9/1/2022
On August 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its interim results for the six months ended June 30, 2022.
-
Filling gap in market: VenusP-Valve™ approved by China's NMPA
7/13/2022
On July 11, 2022, VenusP-ValveTM, Venus Medtech's in-house developed innovative transcatheter pulmonic valve replacement system, was approved by China's National Medical Products Administration for the treatment of severe pulmonary regurgitation in patients after congenital heart defects procedure with native right ventricular outflow tract.
-
Venus Medtech announces 2021 annual results: pacesetter in China and breakthrough-maker worldwide
4/1/2022
On March 31, 2022, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its annual results for the year ended December 31, 2021.
-
Venus Medtech appoints Shakeel Osman as Senior VP of Sales Europe to drive commercialization of TPVR system
3/18/2022
On March 18th, 2022, Venus Medtech ( Hangzhou ) Inc. announced the appointment of Shakeel Osman as Senior Vice President of Sales Europe, responsible for the commercialization of congenital heart devices.
-
Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement
12/7/2021
Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company on December 7th, 2021.
-
Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System
7/28/2021
On July 27, 2021, Venus Medtech Inc., a leading provider of comprehensive interventional heart valve therapy solutions in China, and its controlling subsidiary Renaly Ltd., announced that Professor Martin B. Leon, MD, a pioneer in the field of interventional cardiovascular devices, has been appointed as the Global Principal Investigator for its new-generation renal artery denervation system.
-
Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China
7/14/2020
Venus Medtech Inc., the leading transcatheter heart valve medical device player in China, and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced a collaboration to bring Pi-Cardia's Leaflex™ technology to China.
-
Venus Medtech and Opus Medical Therapies, LLC Announce Partnership for Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Tricuspid Valve Replacement (TTVR) in Greater China Market
5/2/2020
Venus Medtech Inc., the leading Chinese transcatheter heart valve company and Opus Medical Therapies, LLC, a medical device company focused on developing transcatheter mitral and tricuspid valve replacement products for patients undergoing mitral and tricuspid valve disease, announced a partnership agreement to develop, manufacture and sell these TMVR and TTVR products in Greater China.
-
Venus Medtech Announces the Addition of Two Cardiovascular Experts to Their Advisory Team
1/20/2020
The leading transcatheter heart valve medical device player in China - Venus Medtech Inc., is pleased to announce the appointment of two new cardiovascular experts to its advisory team.
-
Venus Medtech Launches Global Advisor Board to Target for International Market
9/24/2018
Venus Medtech has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board.
-
Venus Medtech Enters North American Market
6/14/2018
First Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve in North America was Successfully Performed in Vancouver, Canada
-
Venus Medtech Release: First Successful Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve was Successfully Completed in Brazil
12/22/2017
On December 19, 2017, local time, 4 clinical implantations of transcatheter pulmonary valve VenusP-Valve were successfully completed in Brazil by Professor Carlos Pedra from Dante Pazzanese Institute of Cardiovascular Technology in Sao Paulo, Brazil.
-
Venus Medtech Release: China Successfully Completes the Country's First Human Implantation of a Retrievable Transcatheter Aortic Valve
11/28/2017
- The success of the procedure unleashes a new era for retrievable interventional cardiac valve technology in China [28-November-2017] HANGZHOU, China, Nov. 28, 2017 /PRNewswire/ -- The first human implantation of the VenusA Plus retrievable valve system was completed successfully at the Second Affiliated Hospital of Zhejiang University School of Medicine (SA
-
Venus MedTech Acquires U.S. Company InterValve To Create A Systematic TAVR Treatment And Strengthen Global Expansion
6/14/2017
-
CFDA Approves Venus MedTech's Minimally Invasive Aortic Valve Implant
5/1/2017
-
Venus MedTech's TAVR Device Is Approved By CFDA, Creating A New Era Of Interventional Cardiology In China
4/28/2017
-
Hangzhou's Venus MedTech Forms CV Device Partnership With Keystone Heart
3/6/2017
-
Keystone Heart And Venus MedTech Announce Partnership For Cerebral Embolic Protection With Transcatheter Heart Valve Systems (TAVR) In China And Key Asian Markets
3/2/2017